Napoleone Ferrara
✓ Source-basedrisingItalian molecular biologist
Napoleone Ferrara is an Italian-American molecular biologist who joined University of California, San Diego Moores Cancer Center in 2013 after a career in Northern California at the biotechnology giant Genentech, where he pioneered the development of new treatments for angiogenic diseases such as cancer, age-related...
Also inDeutsch
Photos 1
Awards 7
Connected to Napoleone 6
Valentín Fuster CarullaAlso won Scientific Grand Prize of the Lefoulon-Delalande FondationJohn CharnleyAlso won Lasker-DeBakey Clinical Medical Research Award
Peter WalterAlso won Breakthrough Prize in Life Sciences
Cornelia BargmannAlso won Breakthrough Prize in Life SciencesAxel UllrichAlso won Lasker-DeBakey Clinical Medical Research AwardAbout this person
Napoleone Ferrara is an Italian-American molecular biologist who joined University of California, San Diego Moores Cancer Center in 2013 after a career in Northern California at the biotechnology giant Genentech, where he pioneered the development of new treatments for angiogenic diseases such as cancer, age-related macular degeneration (AMD), and diabetic retinopathy. At Genentech, he discovered VEGF - and made the first anti-VEGF antibody - which suppresses growth of a variety of tumors. These findings helped lead to development and FDA approval of the first clinically effective angiogenesis inhibitor, bevacizumab (Avastin), which prevents the growth of new blood vessels into a solid tumor. Bevacizumab, first approved for treatment of metastatic colorectal cancer in 2004, has become part of standard treatment for a variety of cancers. Ferrara's work led also to the development of ranibizumab (Lucentis), a drug that is highly effective at preventing vision loss in patients with intraocular neovascular disorders such as neovascular AMD and retinal vein occlusion. Ranibizumab and other anti-VEGF agents represent the first effective therapy for such blinding disorders and rank among the most widely used drugs in older adults.
United StatesFame.am measures public visibility signals. It does not measure human value, talent, morality, or credibility.